Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Press release

Regional politicians want TUMT to be introduced as a treatment method for benign prostate enlargement in Halland.

ProstaLund

Stina Isaksson and Carita Boulwén, regional board members (SD) in Region Halland, want TUMT to be introduced as a treatment method in the region.

TUMT, transurethral microwave thermotherapy, is the medical term for ProstaLund's treatment of benign prostate enlargement, CoreTherm®. Region Halland is one of the few regions in Sweden where the method is currently not performed.

Isaksson and Boulwén argue for the introduction of TUMT in Halland and point out, among other things, that neither operating rooms, surgical staff nor hospital beds are needed, as in surgery. Furthermore, they point to the potential savings that the region can make, SEK 3.3 million, if CoreTherm® replaces surgery (TUR-P). "We can treat more patients in our region, without long waiting and journey. More patients will be able to get a cure and it will lead to shorter queues."

They continue: "There would be an opportunity to offer more patients a treatment for their age-enlarged prostate in Region Halland, while at the same time reducing costs and freeing up hospital resources within the strained urological operations by using TUMT besides TURP."

The regional board in Halland decided to give the regional office in Halland to prepare the case.

CEO Johan Wennerholm comments: "It is fantastic that even more politicians are paying attention to the obvious gains that CoreTherm® can contribute to in the healthcare system. With a helicopter perspective, the direct savings as such for the treatment are seen and at the same time what the freed-up resources may lead to, here in the form of more treated patients, shorter queues and hospital resources that can be used for other patient groups. It will be very interesting to hear what conclusions the regional office in Halland comes to. Regardless, we are ready to supply equipment and train personnel!"

For further information, please contact:


Johan Wennerholm,  CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com

About ProstaLund


ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company’s lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:
Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se

Attachments


Regional politicians want TUMT to be introduced as a treatment method for benign prostate enlargement in Halland.

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.